



## Pharmacological Treatment of Hearing Loss

Guest Editors:

**Dr. Magdalena B. Skarżyńska**

Institute of Sensory Organs, 05-  
830 Kajetany, Poland

**Prof. Dr. Piotr Henryk  
Skarżyński**

Teleaudiology and Screening  
Department, World Hearing  
Center, The Institute of  
Physiology and Pathology of  
Hearing, 02-042 Warsaw, Poland

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editors

Hearing loss is recognized as a serious health problem, especially in the generic population, but also in the industrialized environment, where the level of noise can increase hearing loss among children, young, and middle-aged people. To date, there is no widely used pharmacological treatment officially approved by the FDA (Food and Drug Administration) or EMA (European Medical Agency). The prevention of death of hearing cells can be incredibly challenging. For people with severe to profound hearing loss, cochlear implants are the only option, while for less severe cases, hearing aids are possible. As a result, questions about possible, effective, and safe pharmacological treatment are still open.

This Special Issue of ‘Pharmacological Treatment of Hearing Loss’ aims to focus on major developments related to the pharmacological and biological treatment of hearing loss and possible mechanisms (pharmacological approaches of prevention of hearing loss caused by exposure to moderate levels of noise in the workplace (e.g., machinery), recreational environments (e.g., loud music, motorcycles), drug, age-related hearing loss, ototoxic agents, and many other factors.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)